acamprosate vs rivastigmine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and rivastigmine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Exelon
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Rivastigmine (Exelon) is a medicine that helps improve memory and thinking in people with dementia. It works by increasing a chemical in the brain that is important for these functions.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
This medicine treats mild to moderate dementia caused by Alzheimer's disease. It also treats mild to moderate dementia linked to Parkinson's disease. Dementia affects memory, thinking, and the ability to do daily activities.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Rivastigmine helps increase the amount of a chemical called acetylcholine in your brain. Acetylcholine is important for memory and thinking. By increasing this chemical, rivastigmine can help improve these functions in people with dementia.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Nausea
- • Vomiting
- • Loss of appetite
- • Upset stomach
- • Weakness
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Death 2,177
- Fall 1,664
- Hallucination 1,365
- Confusional State 1,258
- Vomiting 885
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
This medicine can cause significant nausea, vomiting, diarrhea, loss of appetite, and weight loss. These side effects can lead to dehydration, which can be serious. If you have a skin reaction that spreads, stop taking this medicine.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
It is not known if rivastigmine will harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if rivastigmine passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking this medicine.
Also Compare, Nearby Drugs
Compare rivastigmine with
How to Read This acamprosate vs rivastigmine Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while rivastigmine sits within the Acetylcholinesterase Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while rivastigmine has 7,349. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or rivastigmine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.